Vaginal Estrogen Cream for Menopause Symptoms

Vaginal estrogen cream treats the dryness, irritation and painful sex of genitourinary syndrome of menopause (GSM), and may ease its urinary symptoms. The North American Menopause Society (NAMS) lists low-dose vaginal estrogen among the effective treatments for moderate to severe GSM.¹ In the United States, the FDA-approved creams contain estradiol or conjugated estrogens.^2,3 Estriol cream is not FDA-approved, though it is widely used in Europe.⁴ Your physician matches the product to your symptoms, your history and your preference.

Genitourinary Syndrome of Menopause and Its Symptoms

Genitourinary syndrome of menopause is the set of vaginal, vulvar and urinary changes that follow the drop in estrogen after menopause. Vaginal atrophy, the thinning and drying of vaginal tissue, is one part of it. You may notice it as vaginal dryness, itching, discomfort or painful intercourse.⁵

NAMS estimates that GSM affects about 27% to 84% of postmenopausal women. It states that GSM is "likely underdiagnosed and undertreated," and that in most cases symptoms can be effectively managed.¹ If you have these symptoms, they are worth raising at your next visit, because effective treatment exists. The stages of menopause explain where these changes fit in the transition.

How Well Vaginal Estrogen Works

Vaginal estrogen delivers estrogen directly to vaginal tissue. A 2016 Cochrane review included 30 randomized trials with 6,235 women comparing creams, tablets, rings and placebo.⁵

More women using estrogen cream reported symptom improvement than women using placebo, based on two trials with 198 women and low-quality evidence.⁵ The review found no difference in efficacy between creams, tablets and rings when compared with each other.⁵ It also found no overall difference in adverse events between the preparations or against placebo.⁵

That result gives you real choice. If a cream feels messy, a tablet or ring may suit your routine, and your physician can switch you, since the review found no difference in efficacy between them. One low-quality finding linked cream to more endometrial thickening than the ring, possibly from higher cream doses.⁵

NAMS sets out a treatment ladder by severity. If your symptoms are mild, non-hormone lubricants and moisturizers sold without a prescription give enough relief for most women. If your symptoms are moderate to severe, low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy and the oral drug ospemifene are effective options.¹ NAMS ties the choice to your symptom severity, each treatment's safety for you, and your preference.¹ The habits in lifestyle changes for menopause sit alongside either path.

FDA-Approved Creams and Compounded Estriol

Two vaginal creams on DailyMed carry FDA labeling for menopausal vaginal symptoms:

• ESTRACE (estradiol vaginal cream 0.01%) is indicated for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.²
• PREMARIN Vaginal Cream (conjugated estrogens) is indicated for atrophic vaginitis and kraurosis vulvae, and for moderate to severe painful intercourse caused by vulvar and vaginal atrophy.³

Estriol cream has no FDA approval in the United States. Estriol "is not FDA approved but is widely used in Europe," according to a 2011 evidence review.⁴ A 2024 systematic review reports that vaginal estriol is the estrogen most often chosen for GSM in Europe.⁷

The estriol evidence spans many studies of modest quality. A 2017 systematic review of 22 studies and 1,217 women found that the studies "confirmed the efficacy of local estrogens" for vulvovaginal atrophy, with few adverse effects.⁶ The authors rated the evidence low to moderate quality.⁶ A pooled review finding does not test the specific cream a pharmacy compounds for you.

If your physician recommends estriol, ask why it fits you better than an FDA-approved estradiol or conjugated-estrogen cream. A clear answer to that question is part of good care.

The Safety Record of Vaginal Estrogen

A vaginal cream acts where you apply it, and some estrogen can reach your bloodstream. The ESTRACE label states that "systemic absorption may occur" and that the warnings for oral estrogen should be taken into account.²

The estriol studies measured this directly, which helps if you are weighing estriol. Serum estriol rose after application, peaking at 1 hour, with no increase at the 6-month follow-up.⁶ The 2024 review found no change in serum estrone, estradiol, testosterone, progesterone or sex hormone binding globulin after vaginal estriol.⁷

The FDA-approved creams carry the class boxed warning for estrogens, covering endometrial cancer, cardiovascular disorders, breast cancer and probable dementia.² The ESTRACE label adds that, in the absence of comparable data, these risks should be assumed to be similar for other doses and dosage forms of estrogens.² Your physician applies the same history check to an estriol cream. The ESTRACE label lists contraindications that include undiagnosed abnormal genital bleeding, a history of breast cancer, active or past blood clots, a past stroke or heart attack, and liver disease.² The PREMARIN label calls for the lowest effective dose and periodic re-evaluation of whether you still need treatment.³ Your physician checks your history against that list before you start.

Large observational data give context for those warnings. In the Women's Health Initiative Observational Study, 45,663 women aged 50 to 79 who did not use systemic estrogen were followed for a median 7.2 years.⁸ Among women with a uterus, risks of stroke, invasive breast cancer, colorectal cancer, endometrial cancer and blood clots did not differ between vaginal estrogen users and nonusers.⁸ The authors concluded the findings provide "reassurance about the safety of treatment."⁸

Two points from NAMS shape your physician's plan. With low-dose vaginal estrogen, a progestogen is not indicated, though endometrial safety has not been studied in trials beyond 1 year.¹ The PREMARIN label, written for estrogen generally, says a progestin should be considered for a woman with a uterus, and your physician weighs both.³ If you have had breast cancer, NAMS finds insufficient data to confirm safety and advises that your treatment consider your needs and your oncologist's recommendations.¹ Bring your oncologist into that decision from the start.

Bladder Symptoms and Recurrent UTI

If you have bladder symptoms, vaginal estrogen also has evidence for the urinary side of GSM.

Incontinence. A 2012 Cochrane review, including trials of local estrogen in 1,464 women, found some evidence that it may improve incontinence. Women using it had about one to two fewer bathroom trips in 24 hours, with less frequency and urgency.⁹ No serious adverse events were reported, though some women had spotting, breast tenderness or nausea.⁹ The same review found that systemic conjugated equine estrogen may worsen incontinence, and one small trial favored pelvic floor muscle training over local estrogen.⁹

Recurrent UTI. A 2021 meta-analysis found that vaginal estrogen reduced recurrent urinary tract infections compared with placebo, across five studies and 1,936 women. Oral estrogen showed no such reduction.¹⁰ Reported side effects of vaginal estrogen included discomfort, irritation, burning and itching.¹⁰

If bladder leaks or repeat infections are part of your picture, tell your physician, because the route of estrogen matters for both. For systemic options, the HRT for menopause guide covers systemic hormone therapy.

The Opt Take on Vaginal Estrogen Cream

GSM is one part of the menopause transition. Your physician reads it alongside your sleep, energy and other symptoms as one hormonal pattern. The Opt Health women's track supports women through perimenopause, menopause and post-menopause.

Care begins with an in-home blood test or a visit to a local lab partner, covering 55+ biomarkers. On the Optimization tier, your plan can include specialized prescriptions for hormone imbalances based on your profile, with up to 4 supplements and 2 prescriptions shipped 4 times a year.

Follow-up labs with a physician consultation repeat 4 times a year on Optimization and twice a year on Foundation. Details are on the women's track page.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.